Recently, an advisory council has been established for the discussion of the National Pharmacare. Many stakeholders including pharmacists are not pleased that they have not been part of the advisory council. I understand the frustration. I agree, pharmacists should be part of this important discussion. But I am also disappointed with the CPhA statement on the Pharmacare Advisory Council.
FDA has recently approved the new antidote for reversal of factor Xa inhibitors – Andexxa® (andexanet alfa). This agent can reverse the effects of rivaroxaban and apixaban. It’s only a matter of time that this reversal agent will become available in Canada. So I think it is time to take a closer look at this new antidote and its role in reversing the effects of anti-factor Xa agents.
I am aware the love for Novel Oral Anticoagulants (NOACs) is growing and that warfarin is falling out of favour, especially in the setting of stroke prevention in atrial fibrillation or in the management of venous thromboembolism. But hear me out on this one. Warfarin should stay and here’s why.
This year for Hypertension Awareness Month and World Hypertension Day (May 17), I want to discuss about the role of single pill combination in the management of hypertension. Single Pill Combination has been consistently recommended in various Hypertension Guidelines to assist with blood pressure control. However, there is no great resource to guide available options of single pill combination in Ontario.
As we begin the dialogue this week on mental health awareness week, I also want to highlight some useful resources for pharmacists. Here are few of my favourites:
Semaglutide (Ozempic) recently received its Notice of Compliance from Health Canada and is therefore now available for Canadians with Type 2 diabetes. So it only makes sense to take a closer look at its evidence, particularly the evidence for its cardiovascular benefits which was studied in SUSTAIN-6 and published in New England Journal of Medicine in 2016..
When a new medication is available, there is often a lot of excitement and hype about how a new option may bring hope to a medical condition. The new medication may offer breakthrough in improving important clinical outcomes (e.g. improving survival, preventing disease complications and significantly offering better quality of life for patients). But before we jump on the bandwagon to start prescribing a new medication, here are few considerations the sales rep may not be quick to highlight or share.